No Data
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Benchmark Co. Maintains Biofrontera(BFRI.US) With Buy Rating, Maintains Target Price $7
Biofrontera's Growth Potential: Buy Rating Backed by FDA Approval and Positive Phase 3 Results
Biofrontera Inc. Reports Record Sales and Strategic Advances
Biofrontera Full Year 2024 Earnings: Misses Expectations
Express News | Biofrontera Shares Are Trading Lower After the Company Reported a FY24 Revenue Miss
